2017-04-11 14:19:37 UTC

AGA and Crohn's & Colitis Foundation Partner to Address Effective Patient-Provider Health Communication in the IBD Community

Program aims to address gaps in effective communication and shared decision-making.

Contact: Aimee Frank

New York, NY (April 11, 2017) — The Crohn's & Colitis Foundation (the Foundation) and the American Gastroenterological Association (AGA), in collaboration with Pfizer, Inc., announced today a partnership to develop a program to jumpstart advances in the area of shared decision-making in inflammatory bowel diseases (IBD). The program aims to identify gaps in effective communication and the lack of research on how providers and patients can make decisions together and prevent suboptimal treatment.

"Partnering with the AGA and Pfizer on such an important project is a natural extension of strong relationships we already have with both organizations," said Michael Osso, President and CEO of the Crohn's & Colitis Foundation. "Working together we will address the critical need to identify tools and mechanisms to support shared decision-making and improve health communication between patients and providers."

According to Timothy Wang, MD, AGAF, AGA President, "The physician patient conversation is integral to ensuring IBD patients are receiving the best care to manage their disease. We are pleased that our work with the Foundation and Pfizer will help identify new ways to facilitate these conversations, which will help health-care professionals provide high-value care."

AGA and the Foundation are convening an expert steering committee, which will help shape and define the project. The program will consist of a national survey of patients and healthcare practitioners to identify gaps in knowledge and use of shared decision-making in IBD, followed by a request for proposals to develop programs based on the identified gaps and needs to be announced in summer 2017. The culmination of the program will result a stakeholder conference to identify innovative programs, current opportunities and challenges, and build an action plan to address current and future needs. Planning and development will take place between 2017 and 2020.

Registration for the Crohn's & Colitis CongressTM is now open. Learn more and register.


About the AGA

The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, the AGA has grown to more than 16,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization. www.gastro.org


About the Crohn's & Colitis Foundation

The Crohn's & Colitis Foundation is the largest non-profit, voluntary, health organization dedicated to finding cures for inflammatory bowel diseases (IBD). The Foundation's mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults who suffer from these diseases. The Foundation works to fulfill its mission by funding research; providing educational resources for patients and their families, medical professionals, and the public; and furnishing supportive services for those afflicted with IBD. For more information visit www.crohnscolitisfoundation.org, call 888-694-8872, or email info@crohnscolitisfoundation.org.


More on IBD

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 14, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 12, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Putting Patients First: Digital Health Tools to Empower IBD Patients

Jan. 18, 2018

Discover how advances in digital health can help you monitor and support IBD patients remotely and dynamically, improve face-to-face care, and drive clinical decisions through shared decision-making.